The Acromegaly Consensus Group considered many of the advances that have occurred in the management of acromegaly over the past 10 years. First, the growth hormone receptor antagonist pegvisomant ...

Biochemical control of acromegaly in noncured patients is usually defined as serum growth hormone (GH) levels <2.0 µg/l, plus normal-for-age serum levels of insulin-like growth factor I (IGF-I).

Causes: Acromegaly occurs when the pituitary gland, a small hormone-making structure in the brain, produces too much growth ...

In our experience, as in that of others, virtually all untreated patients with physical signs of acromegaly have had significant and often striking elevations of plasma growth hormone, even though ...

Pituitary adenomas are tiny lumps which grow within the pituitary gland. These can cause problems by producing extra hormones, for example growth hormone resulting in acromegaly, by preventing the ...

Pituitary adenomas are tiny lumps which grow within the pituitary gland. These can cause problems by producing extra hormones, for example growth hormone resulting in acromegaly, by preventing the ...

The partnership focused on an integrated and accelerated chemistry, manufacturing, and controls (CMC) program for MAR002, Marea's investigational anti-growth hormone receptor (GHR) antibody for the ...